Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,021 Cr
verified against source
Revenue YoY
7%
reported change
EBITDA
₹271 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Ajanta Pharma reported a solid Q1 FY24 with consolidated revenue of ₹1,021 crore (+7% YoY) and EBITDA margin of 26% (+300 bps YoY), driven by gross margin expansion from softer API prices and normalized logistics. PAT grew 19% YoY to ₹208 crore. The India branded business outperformed with 14% growth, gaining market share. US generics grew 19% YoY, supported by new launches and stabilizing price erosion (high single digits). Management maintained mid-teen growth guidance for branded markets and US generics, with EBITDA margin guided at 25%±1% for FY24. Key risks include unpredictable Africa institutional business and potential delays in Chantix launch.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects mid-teen percentage growth for the full year across branded generics and US generics.
- EBITDA margin guided at 25% ±1% for FY24, supported by gross margin stability and cost control.
- US generics revenue expected to remain at similar levels as Q1 (₹213 crore) for the next three quarters.
- Capital expenditure for FY24 estimated at ₹200 crore, including maintenance and new corporate house CapEx.
Risks flagged
- Africa institutional (anti-malarial) sales declined 16% YoY due to unpredictable procurement agency funding.
- Chantix launch depends on FDA approval; management could not provide a firm timeline, citing regulatory dependence.
- While price erosion has moderated to high single digits, further acceleration remains a risk given market dynamics.
Key quotes
- We continue to grow faster than the IPM by 400 basis points, with Ajanta growing at 15% against IPM growth of 11%.
- We retain our guidance of about 25% ±1% EBITDA margin for FY 2024.
- We are seeing that into the high single digits, as a average, price erosion.
Research modules